Bristol Myers Squibb Co. (BMY) financials: revenue, earnings and cash flow
Fiscal 2019–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
Bristol Myers Squibb’s revenue went from $26.1B in fiscal 2019 to $48.2B in fiscal 2025, growth of about 10.7% a year.
Net income in fiscal 2025 was $7.1B, a net margin of 14.6%; the best year in this period was 2023 with $8.0B.
Over the twelve months to September 30, 2026, revenue was $50.0B and net income $9.2B.
Free cash flow was $12.8B in fiscal 2025 and positive in 7 of the 7 years shown.
The diluted share count rose 19% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $50.0B | $48.2B | $48.3B | $45.0B | $46.2B | $46.4B | $42.5B | $26.1B |
| Gross profit | $34.6B | $34.3B | $34.3B | $34.3B | $36.0B | $36.4B | $30.7B | $18.1B |
| Operating income | $13.0B | $9.3B | -$8.4B | $8.4B | $7.7B | $8.1B | -$6.9B | $5.0B |
| Net income | $9.2B | $7.1B | -$8.9B | $8.0B | $6.3B | $7.0B | -$9.0B | $3.4B |
| EPS (diluted) | $4.51 | $3.46 | $-4.41 | $3.86 | $2.95 | $3.12 | $-3.99 | $2.01 |
| R&D | $10.6B | $10.0B | $11.2B | $9.3B | $9.5B | $10.2B | $10.0B | $6.1B |
| Revenue growth | — | −0.2% | +7.3% | −2.5% | −0.5% | +9.1% | +62.6% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $10.7B | $14.2B | $15.2B | $13.9B | $13.1B | $16.2B | $14.1B | $8.2B |
| Capital spending | -$1.4B | -$1.3B | -$1.2B | -$1.2B | -$1.1B | -$973M | -$753M | -$836M |
| Free cash flow | $9.3B | $12.8B | $13.9B | $12.7B | $11.9B | $15.2B | $13.3B | $7.4B |
| Dividends paid | $5.1B | $5.0B | $4.9B | $4.7B | $4.6B | $4.4B | $4.1B | $2.7B |
| Buybacks | — | $0 | $0 | $5.2B | $8.0B | $6.3B | $1.5B | $7.3B |
| Stock-based pay | $552M | $553M | $507M | $518M | $457M | $583M | $779M | $441M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash | — | $10.7B | $10.9B | $12.3B | $9.3B | $17.0B | $15.8B | $15.4B |
| Debt | — | $46.9B | $51.0B | $41.2B | $40.4B | $45.4B | $51.3B | $47.0B |
| Equity | — | $18.5B | $16.3B | $29.4B | $31.1B | $35.9B | $37.8B | $51.6B |
| Total assets | — | $90.0B | $92.6B | $95.2B | $96.8B | $109.3B | $118.5B | $129.9B |
| Shares (diluted) | 2.05B | 2.04B | 2.03B | 2.08B | 2.15B | 2.25B | 2.26B | 1.71B |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 69.2% | 71.1% | 71.1% | 76.2% | 78.0% | 78.6% | 72.3% | 69.1% |
| Operating margin | 26.0% | 19.4% | -17.3% | 18.8% | 16.7% | 17.5% | -16.2% | 19.0% |
| Net margin | 18.5% | 14.6% | -18.5% | 17.8% | 13.7% | 15.1% | -21.2% | 13.2% |
| FCF margin | 18.6% | 26.7% | 28.9% | 28.1% | 25.9% | 32.8% | 31.3% | 28.2% |
| ROIC | — | 10.8% | -9.8% | 11.4% | 8.9% | 8.6% | -6.1% | 3.5% |
| ROE | — | 38.2% | -54.8% | 27.3% | 20.4% | 19.5% | -23.8% | 6.7% |
Frequently asked questions
What is Bristol Myers Squibb’s annual revenue?
$48.2B in fiscal 2025 and $50.0B over the twelve months to September 30, 2026.
How much profit does Bristol Myers Squibb make?
Net income was $7.1B in fiscal 2025 (net margin 14.6%).
Is Bristol Myers Squibb’s revenue growing?
No: revenue fell 0.2% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.